Information Provided By:
Fly News Breaks for April 26, 2016
SRPT
Apr 26, 2016 | 07:09 EDT
Oppenheimer analyst Christopher Marai downgraded Sarepta Therapeutics to Perform saying the yesterday's FDA advisory meeting failed to win support for eteplirsen. The FDA typically follows the recommendation of the panel so we do not expect approval of the drug, Marai tells investors in a research note. The stock is likely to open today around $4, which is the company's cash position, he contends.
News For SRPT From the Last 2 Days
There are no results for your query SRPT